• Brand

    Pharmaceutical and healthcare are collectively a highly important business sector for China Grand Enterprises, INC. It includes chemical pharmaceuticals, biopharmaceuticals, Chinese patent medicines, Chinese medicinal materials, Chinese herbal decoction, medical devices, medical cosmetic, pharmacies, chain drugstores, and more.

    China Grand Enterprises Pharmaceuticals & Healthcare (hereinafter referred to as CGE Healthcare) owns multiple subsidiaries such as Huadong Medicine, Grand Pharmaceutical Group, Lei Yunshang Group and Grand Biotech Group. The enterprise has a worldwide marketing network, working closely with over 10,000 Level II hospitals, over 50,000 basic medical institutions and top 100 drugstores.

    CGE Healthcare adheres to the business concept of "technology research-based, patients-centered and market-oriented" and has always taken innovation as the strategic focus. New products have been consistently put to market through the independent R&D platform construction, industry-teaching-research collaborative innovation and international cooperation, guaranteeing the enterprise's sustainable and rapid development. Through more than 30 years of development, the enterprise has formed a business model integrating R&D, production and sales, simultaneously developing traditional Chinese medicines, chemical medicines, biological medicines, medical devices and medical cosmetic; jointly developing domestic and international markets.

    Huadong Medicine

    Huadong Medicine Co., Ltd. (Huadong Medicine) is headquartered in Hangzhou, China. Huadong Medicine covers the entire pharmaceutical industry chain, with pharmaceutical manufacturing as the pillar, while expanding into the pharmaceutical commerce and cosmetic medicine. As a large-scale comprehensive pharmaceutical enterprise, Huadong Medicine integrates R&D, production, sales and modern logistics, with its products covering traditional Chinese medicine, chemical medicine, biological medicine, aesthetic medicine, medical apparatus and instruments.

    The core of pharmaceutical manufacturing of Huadong Medicine lies in its wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd, which is science-driven and patient-oriented. Over the past decade, Hangzhou Zhongmei Huadong Pharmaceutical Co.Ltd has been engaged in the specialized disease, chronic disease and special drugs, and has constructed a complete and leading pharmaceutical manufacturing and R&D system domestically. Now it boasts the core products pipeline surrounding chronic kidney disease, transplantation immunity, endocrine, digestive system and anti-tumor, with many of the 1st line clinical drugs with market advantages in China, becoming the leading enterprise in the research, development and production of specialized drugs for diabetes and transplantation immunology. All its main API has been approved by FDA, with formulation products and production line certified by America and EU, R&D, production, quality management system complies with the dual certification standards of Sino-America and Sino-Europe. In recent years, Huadong has been continuously intensifying its layout in oncology, endocrine and autoimmune disease, thus forming a complete product pipeline focusing on the innovative drugs, improved new drugs and high barrier generic drugs.

    Huadong Medicine has kept investing, holding controlling shares of, and incubating multiple biotech companies with leading technologies domestic and abroad. By virtue of the construction technology of antibody-conjugated drug toxin library by Huida Biotech, the R&D and production capacity of monoclonal antibodies of Qyuns, the polymer linker coupling technology of Novacyte Therapeutics, and the multispecific antibody platform of Doer Biologics, it now has the wholistic R&D capacity of antibody-drug conjugate (ADC). The company has also introduced the hydroxyl dendrimer technology platform of Ashvattha, USA and the proprietary ATAC technology platform of Heidelberg, Germany through license-in agreements, and continued to promote the internationalization of corporate innovation, gradually forming an R&D ecosystem with Huadong characteristic.

    In the field of pharmaceutical commerce, the company has four business segments including pharmaceutical preparation, medical apparatus and instruments, herbs and ginseng, and healthcare industry, covering wholesale, retail, cold chain distribution, e-commerce, hospital value-added services and special health industry, providing customers with comprehensive solutions. Huadong Medicine is the designated service provider of cold chain distribution in Zhejiang Province. In 2021, it obtained the first Cold Chain Enterprise Express Business Operation License in Zhejiang Province, and was qualified for the third-party storage and transportation of vaccines by Zhejiang Provincial Center for Disease Control and Prevention exclusively. Huadong Medicine has become one of the large-scale, powerful, and comprehensive pharmaceutical service providers in Zhejiang Province, and has ranked among the Top 10 domestic large-scale commercial enterprises for many years.

    In the field of Aesthetic Medicine, Huadong Medicine adopts the strategy of "Global Operation Layout and Dual Cycle Business Development", the company implements the global operation and layout with international perspective. It has more than 30 international high-end non-invasive and minimally invasive cosmetic medicine products, the number and coverage of which has made Huadong Medicine at the forefront of the industry. At present, it has four R&D centers including its wholly-owned subsidiaries, Sinclair, in the UK, High Tech in Spain, joint stock company R2 in the US and Kylane in Switzerland, as well as five production bases in Holland, France, the United States, Switzerland and Bulgaria, with its core products launched in more than 60 countries and regions worldwide, forming a comprehensive product portfolio in Aesthetic Medicinen 2022, the company wholly acquired Viora, an international aesthetic medicine energy source equipment company, further expanding the company’s energy source device business, planning to develop “V Women Tech” products focusing on technology-oriented women’s care to realize holistic beauty care for female customers, including face, body and personal private beauty care. Besides, Sinclair's core product, Ellansé, a new collagen stimulator, received NMPA marketing approval and has been officially launched in mainland China in August 2021. At the same time, several potential products are expected to be gradually launched and sold domestic and abroad by 2025, which will foster new growth momentum to the globalization of Aesthetic Medicine of Huadong Medicine.

    Huadong Medicine has been intensively involved in the field of industrial microorganisms for more than 40 years, successfully developed and manufactured a variety of microbial drugs, and built a key technological system for the research, development, and production of microbial products. The scale and technical level of existing microbial fermentation products are in the leading level in the industry. The company's core products, such as Corbrin Capsule, Acarbose, Cyclosporine, Mycophenolate Mofetil, and Tacrolimus, are all industrial microbial products, and have been awarded with two Second Prize of National Science and Technology Progress “Key Technology and Application of New Production Process for Cyclosporine A”, “ Key Production Technology and Industrialization of Acarbose API and Preparation”. The company has two microbial research and development bases (Zhongmei Huadong and Huida Biotech), five industrial bases (Xiangfuqiao in Hangzhou; Qiantang New District in Hangzhou; Jiuyang in Jiangsu; Meiqi in Hubei; Huachang in Anhui), and a complete and independently-operated industrial microbiology department equipped with a domestic first-class industrial microbiology technical team. At present, the company has the largest fermentation monomer workshop and the leading microbial drug production capacity in Zhejiang Province, with its R&D capabilities covering all stages of microbial engineering technologies such as strain construction, metabolic control, separation & purification, enzyme catalysis, and synthetic modification, reserving nearly 100 R&D projects, mainly in four major fields: pharmaceutical APIs and high-end intermediates, special functional chemicals, raw materials of general health and medical aesthetics, and biomaterials and enzyme preparations, thus forming a comprehensive manufacturing system integrating microbial project R&D, pilot testing, commercial production, engineering, and utility system guarantee.

    In recent years, Huadong Medicine has continued to increase its investment in technological innovation, with several projects winning the National Science & Technology Progress Award. At the same time, with outstanding performance and good governance, Huadong Medicine has been honored for many times by Forbes as one of the "Top 50 Best Listed Companies in Asia Pacific", "Top 100 Listed Companies on the Main Board Companies in China", and has also been listed on the Fortune 500 China for consecutive years.

    Grand Pharmaceutical Group

    Grand Pharma Group (hereinafter referred to as "Grand Pharma") is a technologically innovative international pharmaceutical enterprise with core products in three business fields: "pharmaceutical", "nuclear medicine and cardiovascular interventional diagnosis and treatment technologies" and "synthetic bio-industries", and has formed four business structures, including “innovative barrier medical equipment”, “brand name drugs”, “integration and preparations of raw ingredients” and “health products”, and has made forward-looking decisions in strategies of cerebrovascular and cardiovascular precision interventional diagnosis and treatment, radionuclide tumor prevention, and critical care and infection prevention. Grand Pharma gives full play to its "precise and steady business development ability at home and abroad, introduction, digestion and implementation ability to international leading technologies, and excellent marketing and sales ability", aims at the frontier of science and technology innovation, and with the vision of internationalization and technical innovation, prospectively lays out three leading areas in innovation and science and technology around the world, that is, cardiovascular and cerebrovascular precision interventional diagnosis and treatment, radionuclide anti-tumor, and critical illness and anti-infection. Grand Pharma continues to make a global layout of R&D, the group owns five robust R&D platforms geographically located in different countries including that in radionuclide-drug conjugate (RDC) technology,  DNA R&D, mRNA R&D, glycomics R&D; and a technology R&D platform for high-end medical equipment; as well as five R&D centers which include Optics Valley R&D Center in Wuhan, San Diego R&D Center (immunotherapy DNA technology anti-tumor), Boston R&D Center (precision interventional anti-tumor), Belgium R&D Center (mRNA) and Australia R&D Center (antiviral and anti-infection). The group also has over 30 internationally renowned scientists with high profiles and a R&D team of over 600 staff with more than 70% of them hold master and PhD degree. At present, Grand Pharma has production bases in China, the United States, Canada, Germany, and Singapore with comprehensive sales networks covering more than 60 countries and regions around the world.

    Grand Pharma adheres to the concept of interventional treatment without implantation, it has committed to building a leading international platform for cardiovascular and cerebrovascular precision interventional diagnosis and treatment. Hence, in 2021, an all-round deployment has been achieved on the percutaneous coronary intervention, peripheral vascular intervention, nerve intervention, structural heart disease, electrophysiology, and heart failure, and 10 global innovative products have been reserved. Currently, two products, RESTORE DEB and APERTO OTW, have been approved by NMPA for marketing in China. RESTORE DEB is the only innovative coronary interventional balloon with dual indications of primary coronary vascular lesions and in-stent restenosis of its kind; APERTO OTW is the first kidney dialysis drug-coated balloon for dialysis patients. Grand Pharma has made a pipeline design for interventional treatment, radionuclide therapy, and immunotherapy. The company has also realized a comprehensive layout of R&D, production, sales, regulation, and other links in the radionuclides and established a complete industry chain within three years. At present, Grand Pharma owns 16 global innovative products, covering 13 kinds of cancers, which contributes to company into a place as industry-leading status in products number, pipeline and variety. Among them, SIR-Spheres® yttrium [90Y] resin microspheres have been approved by the State Food and Drug Administration in February 2022 for the treatment of patients with unresectable colorectal cancer liver metastasis who cannot be cured through the standard treatments. The Group currently has four global innovative products in stock, where the clinical trial of the innovative drug STC3141 is progressing smoothly. The clinical trials of six drugs for the treatment of sepsis, ARDS, severe COVID-19 infection, and ARDS caused by COVID-19 infection have been approved in China, Australia, Belgium, the United Kingdom, and Poland, further promoting the international multicenter clinical trial of drugs. For mRNA research, the mRNA vaccine R&D center of Nanjing AuroRNA Biotechnology Co., Ltd. (AuroRNA) jointly established by Grand Pharma and eTheRNA Immunotherapies NV in Belgium has been officially put into operation. It is set up with the laboratory used for early project research and formulation development and has independent R&D capacities with a productivity meeting the clinical research requirements of therapeutic and preventive mRNA vaccines at all stages, equipping with the capability to compete with the global mRNA leaders. In the traditional respiratory and otorhinolaryngology department, Grand Pharma has developed five innovative products that are in the late-stage clinical trials or have been marketed abroad for the treatment of dry eye, pterygium, post-operative anti-inflammatory analgesia in ophthalmology, allergic rhinitis, and severe allergic reactions.

    Grand Pharma has been intensively involved in the field of synthetic biology for many years and has now developed into one of the world's leading companies for the large-scale production of high-quality amino acid products through biological manufacturing. It is committed to serving the biotech health industry through the production of high-quality amino acid products, with the main products covering more than 20 amino acids and derivatives such as taurine, cysteine series, arginine series, and tyrosine series, which are exported to more than 60 countries and regions around the world, accounting for more than 60% of the total business amount. The market share of some amino acid products has also reached a world-leading level. The production capacity of taurine and the core product of the amino acid industry rank second in the world, while the production capacity of cysteine ranks first in the world. After years of continuous hard work by the R&D team, Grand Pharma has established comprehensive technical advantages in the development of industrial strains and fermentation process control based on synthetic biology, metabolic engineering, and fermentation engineering. It has also built a fermentative production process centering on strain genetic modification and an enzyme production process centering on enzyme catalysis, and has applied biomanufacturing technology to replace the traditional chemical synthesis process. The advanced production technology and some processes have closed the gaps in China and greatly reduced CO2 emissions during production.

    In the future, Grand pharma will continue to focus on patients’ needs, adhere to the principle of innovation drives. Guided by the development concept of “comprehensive advantages, innovation barriers and global expansion”, great efforts will be continually made to strive for the formation of a new pattern of joint development and mutual reinforcement in home and aboard by adopting the strategy of combining self-independent innovation and global expansion and seeking development with global operation and dual-cycle business development. All the efforts show company dedication to become a scientific and innovative international pharmaceutical enterprise respected by doctors and patients, and ultimately serving the society.

    Leiyunshang Group

    Founded in 1734, Lei Yunshang group is one of the four most renowned pharmaceutical groups in China. Among the first batches of historical Chinese brands, it is also the owner of top-secret national projects and intangible cultural heritage. With the unified brand of “Lei Yunshang”, inheriting a history of nearly 300 years, it committed to the mission of “aggregating medicinal herbs across-the-board to benefit thousands of people”, with the brand´s proposal to “convey the wisdom of health with a 300-year history”, and strictly follows the ancestral teachings of "selecting genuine medicinal materials to produce high-quality medicines, following the principles of manufacturing the quality pill, pulvis, emplastrum, unguentum and pellet". Based on succeeding and carrying on the essence of the theory of epidemic febrile disease, and the fundamentals of traditional Chinese medicine, while fully integrating modern scientific achievements, Lei Yunshang Group is actively transforming into an innovative Chinese medicine manufacturing enterprise driven by both technology and strong branding. With technological improvement, research, and development innovation in hand, it has become a primary traditional Chinese medicine group with unique advantages in multiple therapeutic fields and will become a leading enterprise in China's pharmaceutical industry.

    Lei Yunshang has a rich product pipeline, covering 8 clinics treatment fields, which include the respiratory system, urinary system, tonics, digestive system, gynecology, pediatrics, brain medicines, cardiovascular and cerebrovascular diseases, and antineoplastic drugs. The main types of drugs are tablets, powders, granules, pills, capsules, and ointments. Lei Yunshang is the owner of a variety of national secret formulas and national protected varieties of traditional Chinese medicine. Moreover, the group has multiple products by application of national top-secret formulas listed in the national intangible cultural heritage catalog, such as Liushenwan, Jianyanling Capsules "National Drug Approval No.1", Kuhuang products, Bufei Huoxue capsules, Xiaozheng Pills, Congrong Yizhi Capsules, Naoan drop Pills, and Lingbao Huxin Pills. Lei Yunshang has formed a dimensional product pattern specialized in the respiratory and cardio-cerebrovascular market, incorporating advantages in characteristic medicinal products in the Chinese patent medicine market, focusing on major diseases and cultivating large varieties.

    Lei Yunshang Group always adheres to the principle of patient-centered and complies the integrity and innovation of traditional Chinese medicine in combination with modern technology. By building the whole evidence-based product chain, Lei Yunshang continuously improves the scientific connotation of the product and its competitiveness in the market. With the collaboration of national and academic research institutes, experts, scientists and an R&D consultancy team, Lei Yunshang Group has built four R&D platforms, a technology platform for the preparation of Chinese medicine mini-pills, a Chinese medicine quality analysis technology platform, respiratory drug efficacy assessment technology platform and liposome research and development platform. We collaborate with the team of Prof. Dr Zhong Nanshan, State Key Laboratory of Respiratory Diseases (Guangzhou Medical University), to elucidate the anti-inflammatory and antiviral mechanism of Liushen products using modern biomedical technology. Liushen Pills, under the title of Heritage Classic Chinese Patent Medicine, have been ranked second in the Scientific and Technological Competitiveness List of Traditional Chinese medicine in China. Meanwhile, a multicenter, randomized, double-blind, placebo-controlled study of Bufei Huoxue capsule was conducted to treat COVID-19 patients during their recovery. It found that the capsule could significantly improve patients’ exercise tolerance, relieve their fatigue, and improve their quality of life. The research results have been published in international journals in Pulmonary Circulation and Ethnopharmacology. The findings are well accepted in the academic and medical community. In the urological field, with more than 20 years of clinical application, it has been proved that Shenshuaining Capsules can interfere with the progression of nephropathy with multiple targets, improves the clinical symptoms of patients with chronic renal failure. It also increases eGFR, effectively reduces creatinine, and urea nitrogen, stabilizes residual renal function and delays the progression of nephropathy. In the field of toning, Jianyanling Capsules have evolved from the prescribed experience of "Buyi Shenqi Jingxue Formula" of Traditional Chinese Medicine Master Shi Jinmo, who was one of the four most famous doctors in Beijing at the time. It has become the first national health medicine with anti-fatigue, anti-ageing and life-prolonging action. Jianyanling Capsules which is worthy of the name of "No. 1" tonifying medicine. In the field of orthopaedics, Qianggu capsules have been used for the treatment of primary osteoporosis. It can effectively improve the basic properties of bone biomechanics, relieve pain, prevent inflammation, and improve microcirculation. The development of Qianggu capsules was within the project of the 8th Five-Year Plan of the National Administration of Traditional Chinese Medicine, the 9th Five-Year Plan of the National Science and Technology Commission, the 10th Five-Year Plan of the National Planning Commission, and a major transformation project for Scientific and Technological Achievements in Beijing. In the field of digestion, the use of artificial liver technology based on tissue engineering further demonstrated that the exact role and key mechanism of Kuhuang series products in the emergency record of endoplasmic reticulum, oxidative damage, liver fibrosis, normalizing gallbladder to cure jaundice, reliving steatosis, immune regulation and reconstruction, liver cell regeneration and apoptosis. In the field of gynecology and pediatrics, Gynecological medicine Xiaozheng Pills clarified the possible mechanism of action and potential therapeutic targets. The study combined the methods of network pharmacology, serum metabolomics and molecular biology technology. This research project won the second prize in the Suzhou Science and Technology Progress Award and the second prize of the Jiangsu Traditional Chinese Medicine Science and Technology Award. In the field of brain, through modern clinical studies, it can be found that Congrong Yizhi capsules could increase the degree of activation of brain regions, prevent hippocampal atrophy, inhibit T - tau protein aggregation, and improve cerebral blood flow and vascular endothelial function, to fill the gaps of Chinese patent medicine in the field of treatment of dementia in China. As the first TCM product in the treatment of dementia, the mechanisms research project has won the prize in China University of Science and Technology, the National Scientific and Technological Progress Prize, and several other honours. As a result of the national "Eighth Five-Year Plan" research project, Naoan drop pills can effectively inhibit thrombosis formation, inhibit platelet aggregation, increase blood supply to the brain, protect ischemic brain tissue and reduce oxidative stress. In the cardiovascular field, Lingbao Huxin Pills are used for atherosclerosis and myocardial ischemia. It also showed a significant curative effect in bradycardia by multi-channel and multi-target treatment. In the field of oncology medicine products, Chinese anticancer medicine first Brucea oil emulsion injection and Brucea oil oral solution, are widely used in the clinical treatment of lung cancer and metastasis in the brain and digestive tract. For decades, the product has benefited countless patients.

    Relying on its advantages, Lei Yunshang Group strictly controls the quality of medicinal ingredients, strengthens its quality controls of the medicinal materials from birthplace as well as intensifies the drug safety control throughout the entire production process by establishing medicinal ingredients bases in the original production area. At present, nearly 100 such cultivation bases have been built to ensure product safety and efficacy. Also, the group introduced Lei Yunshang medicinal material traceability system to trace the products and raw ingredients throughout the supply chain in both forward and reverse directions, which can trace back to the source of the medicines and trace forward to the destination, control quality, and detect the person responsible. This effectively guarantees the quality and safety of products in all processes.

    Lei Yunshang Group adhered to the integrity and innovation of traditional Chinese medicine will continue to pass on the essence of traditional Chinese medicine and combines Traditional Chinese Medicine with modern evidence-based research. To promote the modernization and industrialization of traditional Chinese medicine, Lei Yunshan will continue to work on basic research and product line expansion to achieve the creative transformation and innovative development of traditional Chinese medicine with a focus on the patient, thereby contributing to the people’s health.

    Grand Life Sciences Group


    Grand Life Sciences Group Co., Ltd. (“GLS Group”) is state-of-the-art comprehensive pharmaceutical enterprise adhering to a fully integrated system of Research & Development (R&D), production and sales of pharmaceutical products. Guided by the innovative R&D concept of self-reliance, uniformity and internationalization, GLS focuses on portfolio of immunity, infection, perioperative and critical care management, digestion, metabolism, hematologic system and wound management. GLS spares no effort to provide patients around the globe with versatile and whole industry chain services in health management, disease prevention, and disease treatment.

    GLS Group thoroughly analyzes the future industry transformation trend, aiming at innovative drug research and development, based on the domestic and global unmet clinical needs. GLS has established R&D centers and production bases in more than 10 cities (Beijing, Chengdu, Hangzhou, Shenyang, Wuhan, Chongqing, Nanjing, Zhengzhou, Yantai, and Anshan), leaning on technology platforms for vaccines, probiotic drugs, recombinant protein, blood products, polymer materials, chemical drugs, and collagenase. GLS Group is committed to the development and production of sophisticated blood products, innovative recombinant vaccines, new generation live biotherapeutic products, nano targeted formulations, biodegradable polymers medical devices and high-value APIs.

    In the field of vaccines, GLS's adjuvant-free rabies vaccine for human use has been marketed for many years, with stable quality and high market reputation. Grand theravac life science (Nanjing) Co.,Ltd Vaccine R&D Center has been established to study recombinant proteins and mRNA vaccines. This center has been equipped with a vaccine R&D platform with independent intellectual property rights, a modern pilot workshop for recombinant protein vaccines, and A2 and P2 biosafety laboratories, which meets the requirements of R&D, pilot-scale production, sample preparation for phase I and phase II clinical trials, and others. There are more than 10 innovative vaccine R&D pipeline projects, and many are currently under clinical research. TVAX-008, the first hepatitis B vaccine is undergoing phase I clinical trial, which is expected to fill the space of the chronic hepatitis B vaccine research. In 2021, the project on the therapeutic hepatitis B vaccine was listed as the key R&D project of Jiangsu Province and received provincial special support grants.

    In the field of live biotherapeutic products, Hangzhou Grand Biologic Pharmaceutical Inc. is recognized as one of the leading companies in China. The leading brands are Siliankang (Bifidobacterium quadruple viable tablet) and Misang (Clostridium butyricum Capsule) which are among the best in the market, are widely recommended by the National Reimbursement Drug List and standard clinical guidelines. Relying on the resource pool of 10,000 strains of functional microorganisms with independent intellectual property rights, the company has built a platform for gene editing and genetically engineered bacteria, focusing on the development of Live biotherapeutic products of the next generation in the field of digestion, metabolism, immunity, infection, and other more innovative products.

    In the field of blood products, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (“SHUYANG”) under GLS Group ranks among the top 20 Chinese biomedical enterprises. It has a state-of-the-art production facility for blood products, whose monomer production capacity is the topmost in Asia and among top 10 in the world. The facility meets Chinese GMP standards and EU and WHO standards and its human albumin, human immunoglobulin for intravenous injection, human fibrinogen, and other products not only meet the domestic demands but also have been exported to more than 10 countries. Looking to the future, SHUYANG will continue to improve its blood products R&D and production, aiming to become a global high-quality service provider of the whole series of blood products. In 2021, the human fibrinogen product was approved by the National Medical Products Administration (NMPA), indicating that SHUYANG has taken an important step forward in the field of coagulation factors. In the future, the company will also focus on the R&D of the whole series of blood products and proceed more explorations in the fields of trace protein and rare diseases.

    In the field of chemical medicines, the four production bases (Grand life sciences Liaoning, Grand life sciences Wuhan, Penglai Nuokang, and Anshan Weibang) have enabled GLS Group to take full advantage of the industrial system and the integration of active pharmaceutical ingredients (API) and formulations and focus on competitive fields. GLS has set up a nano-targeted drug R&D center, an R&D and production transformation platform for enzyme engineering and polymer materials, an API base, and a Peru snake venom supply base to deliver authentic biopharmaceuticals, emulsions, and other complex high-end formulations and medical devices with biodegradable materials. At the same time, it also focuses on establishing a perioperative product group, including hemostasis, anesthesia, analgesic, and anticoagulant, with core products including Baquting®, Anfu®, Kaitong®, Andejian®, and Dianjiejing®. Baquting® dominates the domestic hemostatic drug market. Anfu® is China’s first domestic targeted analgesic injection, and Dianjiejing® is the only enzymatic debridement drug officially approved domestically and abroad.

    GLS Group will continue to innovate management ideas, to be clinical needs-driven, R&D-based, patient-centric, and market-oriented, and strive to become a global top-class enterprise in the field of life sciences relying on a combination of a large-scale industrial system, efficient allocation of resources, focus on core fields, and strengthening high-end talent pool.


    With the acceleration of China's medical system reform, guided by the enterprise spirit of "loyalty, simplicity, diligence and innovation", CGE Healthcare will adhere to the principle of quality first and development through innovation, always take "serving the society" as the highest mission, expand future business through innovative cooperation, and continuously make contributions to the society.